Oncology

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

Cancer PSA features scientists

Stand Up To Cancer is kicking off a PSA that features Grammy-winner Jennifer Hudson and a Genentech scientist.

Imbruvica lassoes CLL indication

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February.

AZ seeks blood test to ID potential patients

AstraZeneca's hope is that the blood test could replace tissue samples and be used to identify patients who could benefit from its lung drugs.

Bayer's Nexavar disappoints in breast cancer

The drug did not hit its Phase III primary target of improving progression-free survival.

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

By

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead's idelalisib hat trick

The FDA greenlighted the drug for three cancers.

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

NIH: HPV test beats Pap for cancer assessment

HPV testing provides an edge over Pap screenings when it comes to detecting cervical cancer risk.

Roche seeks Avastin cervical-cancer indication

Roche seeks Avastin cervical-cancer indication

By

The FDA granted Priority Review for consideration of Avastin for some cervical-cancer patients.

Lilly's Cyramza misses liver-cancer target

Cyramza patients had more favorable overall survival rates than placebo patients, but the differences were not statistically significant.

BMS readies nivolumab for melanoma filing

BMS readies nivolumab for melanoma filing

By

Bristol-Myers Squibb is moving forward with its FDA filing of PD-1 Opdivo (formerly known as nivolumab) for patients with advanced melanoma who have been previously treated with the BMS drug Yervoy.

Experiment cuts cancer costs, ups drug spend

UnitedHealthcare finds drug costs more than doubled.

FDA wants male breast cancer patients

The regulator wants men to be part of breast cancer clinical trials.

Panel votes against AZ's olaparib

Panel votes against AZ's olaparib

By

An FDA advisory panel voted 11-2 against an accelerated approval for AstraZeneca's experimental PARP inihibitor. The panel recommends getting more data before giving the drug the all-clear.

Lilly drug misses Phase III target

Eli Lilly's gastric cancer drug Cryamza failed to hit its primary Phase III liver cancer target.

Dendreon CEO resigns

August 15 is John Johnson's last day as president and CEO.

Everyday Health rolls out CancerRx app

Everyday Health rolls out CancerRx app

By

The bedside decision-making app includes clinical trial and drug information as well as breaking news.

ASCO highlights immuno-oncology challenges

ASCO highlights immuno-oncology challenges

By

The potential of immunotherapy is great, but the news from the 2014 medical meeting shows that great may not be gargantuan in terms of treatment reach.

Insurers pay docs to stick to regimens

Companies including WellPoint and Highmark are deploying financial incentives for doctors to stick with recommended cancer treatments.

BMS enters two immuno-oncology deals

The drugmaker has paired up with Incyte and CytomyX in two separate deals.

GSK drug fails in lymphoma bid

GSK drug fails in lymphoma bid

By

The companies announced Tuesday that Arzerra, already indicated for leukemia, failed to outdo Roche's Rituxan in the lymphoma setting.

Xtandi seeks first-line status

The FDA has granted priority review status for the expanded-indication review.

Big Pharma's big cancer bet

Big Pharma's big cancer bet

By

Pharma has sunk a lot of money into a field that saw $91 billion in sales last year. But those bets come amid turmoil in the US healthcare market, including a tussle over price.

Poll finds most doctors OK with Iclusig

A survey by investment firm Jefferies found that the temporary 2013 suspension had a minimal impact on how doctors perceive the drug.

Pfizer posts weak Q1 sales, stands by AZ offer

Pfizer posts weak Q1 sales, stands by AZ offer

By

CEO Ian Read told investors Monday that an AZ merger would benefit Astra shareholders and add oomph to its marketing potential. Another exec said he could "envision" filing palbociclib this year, but made no promises.

Latest Breakthrough nod goes to Novartis

The FDA announced Tuesday its approval of lung cancer drug Zykadia for patients with metastatic ALK-positive non-small cell lung cancer.

Merck Q1 sales fall, but diabetes rises

Merck Q1 sales fall, but diabetes rises

By

Sales of its big diabetes franchise rose 3% vs. the same period last year, while drops in Singulair and Nasonex revenue marked the quarter. The company is slated to reveal pipeline progress next week.

Lilly Q1 sales dip

Lilly Q1 sales dip

By

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

GSK, Novartis, Lilly play musical chairs

GSK, Novartis, Lilly play musical chairs

By

The three drugmakers rearranged part of the pharma universe Tuesday with a string of pipeline-altering deals.

Email Newsletters